Semax and Selank: How the Two Russian Neuropeptides Compare

Semax and Selank are usually mentioned in the same breath. Both are short synthetic peptides developed in Russia, both are delivered intranasally in their home market, and both are marketed in the US as cognitive or "nootropic" peptides. The pairing is so common that "semax selank" is searched as a single phrase. But the two compounds come from different parent molecules, are studied for different effects, and — as of 2026 — sit in very different places with the FDA. This guide compares Semax and Selank side by side so the differences are clear.

This article is educational and written for licensed prescribers. It is not medical advice, and it does not recommend a dose for any patient.

Semax and Selank at a Glance

The shared Pro-Gly-Pro tail is not a coincidence. Both peptides came out of the same Russian research program, which extended short, naturally occurring peptides with that tripeptide to slow their breakdown. The "front half" of each molecule is what makes them different.

What Each Peptide Is

Semax: An ACTH-Derived Neuropeptide

Semax is built on a fragment of ACTH, the pituitary hormone that drives cortisol release — but the fragment used has no meaningful hormonal (corticotropic) activity. Research has focused instead on its effects in the brain: brain-derived neurotrophic factor (BDNF) expression, dopaminergic and serotonergic signaling, and neuroprotection in models of ischemia. In Russia, it is used in neurological settings including stroke and cognitive impairment.

Selank: A Tuftsin-Derived Anxiolytic

Selank is built on tuftsin, a four-amino-acid peptide that is part of the immune system's signaling repertoire. Research has focused on anxiety and stress: Selank has been studied for effects on GABAergic signaling, monoamine metabolism, and the expression of immune-signaling molecules in the brain. In Russia, it is registered as an anxiolytic.

How Their Mechanisms Differ

Semax: Neurotrophic and Activating

The mechanism most associated with Semax is increased expression of BDNF, a growth factor involved in neuronal survival and synaptic plasticity, along with modulation of dopamine and serotonin systems. Its reported profile is activating — associated with attention and mental energy — which is why it is marketed for focus and cognitive performance.

Selank: Anxiolytic and Neuroimmune

Selank's research emphasizes anxiety reduction without sedation. Proposed mechanisms include modulation of GABA-A receptor signaling, effects on enkephalin-degrading enzymes, and influence on cytokine signaling in the central nervous system. Its reported profile is calming rather than stimulating.

Why They Are Paired

Because one is described as activating and the other as calming, they are often discussed together as complementary — Semax for focus, Selank for anxiety. That rationale is a theory of practice, not a finding: there are no published controlled trials of Semax and Selank used together.

What the Evidence Shows

Strengths and Limits of the Russian Literature

Both peptides have human clinical literature, which sets them apart from compounds like dihexa that have only animal data. But that literature comes predominantly from Russian academic and clinical centers, often from the groups that developed the compounds. Study sizes are generally small, designs vary, and independent replication in large, randomized Western trials is largely absent. For Semax specifically, FDA's July 2026 review found no human pharmacokinetic studies by any route and noted that the published clinical literature covered intranasal use only.

Intranasal Delivery

Both peptides are delivered as nasal drops or sprays in Russia. The intranasal route is thought to offer a partial pathway to the brain along the olfactory and trigeminal nerves, which may matter for short peptides that are broken down quickly in the bloodstream. Selank's plasma half-life in animal models has been estimated at under ten minutes, which is part of why the nasal route is emphasized.

Intranasal delivery also brings uncertainties: absorption varies with technique and nasal anatomy, and the amount that actually reaches the brain in people has not been well quantified. For Semax, FDA specifically noted that there are no safety data for the subcutaneous route that US nominations proposed — the route studied abroad and the route proposed here are not the same.

Regulatory Status in 2026

The two peptides have diverged sharply.

Semax. At the July 24, 2026 Pharmacy Compounding Advisory Committee (PCAC) meeting, FDA proposed that Semax (free base and acetate) not be added to the 503A Bulks List, citing insufficient characterization, no human pharmacokinetic data, no safety data for the proposed route, and a rodent signal that Semax potentiated amphetamine-induced dopamine release. Russian registration does not create a US approval or compounding pathway. As a result, compounded access to Semax in the US is in serious doubt. See Semax and the FDA 503A decision and the earlier Semax FDA status explainer.

Selank. Our FDA peptide status tracker lists Selank in Category 1 — under evaluation, the interim category under which FDA does not currently intend to take action against 503A compounding with the substance, subject to the other 503A conditions. The site's April 2026 Category 2 update lists Selank among the 12 peptides removed from Category 2. Category 1 is interim, not a final determination.

Check the tracker for current status of either compound.

Safety Considerations

• Semax: Reported adverse effects in the clinical literature are generally mild (nasal irritation is most often described), but FDA concluded the human safety profile is insufficiently characterized. The amphetamine-potentiation signal in mice is relevant for patients with stimulant use or a history of substance misuse.
• Selank: Reported adverse effects in published studies are generally mild; systematic long-term safety data are lacking.
• Both: Product quality is a real risk for anything sold as a "research chemical." Neither is appropriate in pregnancy or breastfeeding given the absence of data.

Frequently Asked Questions

What is the difference between Semax and Selank?

Semax is derived from a fragment of ACTH and is studied mainly for neuroprotection and cognition; Selank is derived from tuftsin and is studied mainly for anxiety and stress. Both carry the same stabilizing Pro-Gly-Pro tail and are delivered intranasally in Russia.

Can Semax and Selank be used together?

They are often discussed together as a complementary pair — Semax for focus, Selank for calm — but there are no published controlled trials of the combination. The pairing rationale is a theory of practice, not an evidence-based finding.

Is Semax or Selank FDA-approved?

Neither is FDA-approved. Both are registered medicines in Russia, which does not confer US approval.

Can Semax still be compounded in the US?

FDA proposed in July 2026 that Semax not be added to the 503A Bulks List, so compounded access is in serious doubt. The proposal is an advisory step, not a final rule — check the FDA peptide status tracker for current status.

What is Selank's FDA status?

Selank is listed in Category 1 (under evaluation) on our tracker and was among the peptides removed from Category 2 in April 2026. Category 1 is interim; its status can change.

Where can I learn about Semax dosing?

See our Semax dosage guide, which explains what the research used and why no US dose is established. Selank has no established US dose either; its background and research are on the Selank page.

Newtropin does not prescribe, compound, or dispense. We connect licensed providers with a licensed 503A compounding partner; prescribers can start at For Providers. For the broader picture, see our nootropic peptides guide.